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Essentials 
• Venous thromboembolism (VTE) is associated with family history of myocardial infarction 
(FHMI) 
• VTE cases and a sub-cohort from the Tromsø and the Nord-Trøndelag Health Studies were 
genotyped 
• The risk of VTE by FHMI could not be explained by the prothrombotic genotypes 










Background: Family history of myocardial infarction (FHMI) is known to increase the risk of venous 
thromboembolism (VTE).  
Objectives: To investigate the effect of prothrombotic genotypes on the association between FHMI 
and VTE in a case-cohort recruited from a general population. 
Methods: Cases with a first VTE (n=1,493) and a sub-cohort (n=13,072) were sampled from the Tromsø 
study (1994-2012) and the Nord-Trøndelag health (HUNT) study (1995-2008). DNA-samples were 
genotyped for rs8176719 (ABO), rs6025 (F5), rs1799963 (F2), rs2066865 (FGG) and rs2036914 (F11). 
Participants with missing information on risk alleles (n=175), FHMI (n=2769) and BMI (n=52) were 
excluded. Cox-regression models were used to estimate hazard ratios (HRs) with 95% confidence 
intervals (CI) for VTE. To explore the role of prothrombotic genotypes for the association between 
FHMI and VTE, we (i) included the genotypes in the multivariable-adjusted models, and (ii) assessed 
the joint effects between FHMI and genotypes on VTE risk.  
Results: FHMI was associated with a 1.3-fold increased risk of VTE (HR 1.32, 95% CI 1.16-1.50) and 1.5-
fold increased risk of unprovoked VTE (HR 1.47, 95% CI 1.22-1.78). The risk of VTE by FHMI did not alter 
after adjustment for the five genotypes. The combination of FHMI and the different prothrombotic 
genotypes did not result in an excess VTE risk (i.e. no biological interaction).  
Conclusions: Our findings suggest that the risk of VTE by FHMI is not explained by rs8176719 (ABO), 
rs6025 (F5), rs1799963 (F2), rs2066865 (FGG) and rs2036914 (F11). FHMI combined with 
prothrombotic genotypes had an additive effect on VTE risk. 
 






Traditionally, arterial thrombotic diseases (e.g. myocardial infarction [MI] and stroke) and venous 
thromboembolism (VTE) (deep vein thrombosis [DVT] and pulmonary embolism [PE]) have been 
considered as separate disease entities with different pathophysiology and treatment. However, both 
registry-based studies and cohorts recruited from the general population have demonstrated 
bidirectional associations between arterial and venous thromboembolic diseases [1-4].  The 
relationship between arterial and venous thrombosis may be attributed to shared environmental or 
genetic risk factors, or it may be a causal association through mediating factors, such as hospitalization 
accompanied by immobilization and infection, or via a transient prothrombotic state following an 
arterial event [5]. Results from population-based cohorts have revealed that among the well-known 
cardiovascular risk factors, only advancing age, obesity and family history of MI (FHMI) were shared 
risk factors for arterial and venous thromboembolic diseases [6-11]. 
FHMI is a well-established risk factor for MI [11-13], and during recent years, FHMI has also 
been found to be associated with an increased risk of VTE [9-11, 14]. The population attributable 
fraction (PAF) of MI and VTE by FHMI has been estimated to be 19% and 13%, respectively [11], 
indicating that 19% of the total incidence of MI and 13% of the total incidence of VTE could be 
explained by FHMI-related risk factors. Due to the impact of FHMI on the risk of MI and VTE, it is 
important to unravel underlying mechanisms and potential common pathways. Although it is unclear 
how FHMI contributes to the risk of VTE, it might be due to shared environmental or genetic risk factors 
or mediated by an effect of a previous arterial cardiovascular disease. Previously, we reported that 
modifiable cardiovascular risk factors slightly attenuated the association between FHMI and MI, but 
had no effect on the association between FHMI and VTE. Furthermore, by applying a cause-specific 
model to eliminate the effect of MI on VTE, we showed that MI did not mediate the effect of FHMI on 




As the risk of VTE by FHMI was particularly pronounced for unprovoked VTE events and 
increased with the number of affected relatives [11], it is plausible to assume that prothrombotic 
genotypes accumulating in families with arterial cardiovascular disease might explain the association 
between FHMI and VTE. Several genetic polymorphisms associated with an increased risk of VTE  have 
been discovered during the last decades [15]. Some of these prothrombotic genotypes, such as 
rs8176719 (ABO), rs6025 (F5), rs1799963 (F2), have also been shown to increase the risk of arterial 
thrombosis in some studies [16-18]. 
It is unknown whether prothrombotic genotypes are shared risk factors for FHMI and VTE, and 
how a combination of these factors influence the VTE risk. We therefore aimed to (i) investigate 
whether the association between FHMI and VTE was explained by the presence of prothrombotic 
genotypes and to (ii) explore the combined effects of FHMI and prothrombotic genotypes on the risk 




Study participants were recruited from the fourth survey of the Tromsø study (Tromsø 4) conducted 
in 1994-1995 [19],  and the second survey of the Nord-Trøndelag Health Study (HUNT 2), conducted in 
1995-1997 [20]. The Tromsø Study and the HUNT Study are population-based cohorts of inhabitants 
in Tromsø municipality and Nord-Trøndelag County, Norway, respectively. To Tromsø 4, the entire 
population aged ≥25 years living in the municipality of Tromsø was invited to participate, and 27,158 
participants attended (77%). To HUNT 2, all residents in Nord-Trøndelag County aged 20 years and 
older were invited to participate, and 66,140 participants attended (71%) [20]. More detailed 
descriptions of the studies have been published elsewhere [19, 20]. 
All participants from these surveys were followed from the date of inclusion until a verified 




31, 2012 in the Tromsø Study). In the Tromsø Study, all incident VTE events were identified by 
searching the hospital discharge diagnosis registry, the autopsy registry and the radiology procedure 
registry at the University Hospital of North Norway. The medical record for each potential case of VTE 
was reviewed by trained personnel, and adjudication criteria for VTE were the presence of clinical signs 
and symptoms of DVT or PE combined with objective confirmation by radiologic procedures that 
resulted in treatment initiation (unless contraindications were specified). In the HUNT study, VTE 
events were identified by searching the hospital discharge diagnosis registry and the radiology 
procedure registry at the two local hospitals in the county (Levanger Hospital and Namsos Hospital) 
and by searching the discharge diagnosis registry of the tertiary-care center of the region, St. Olav’s 
Hospital in Trondheim (Sør-Trøndelag County). The medical records for potential VTE cases were 
reviewed and validated by two physicians, and the VTE diagnosis required positive objective 
confirmation by radiologic procedures. Detailed descriptions of identification and validation of VTE 
events in the two studies have been published elsewhere [21, 22]. 
All cases with an incident VTE (n=1,493) and a randomly selected sub-cohort (n=13,072) of 
participants without previous VTE were included in our study (Figure 1). Due to the study design, in 
which all participants in the original cohort has an equal chance of being included in the sub-cohort, 
217 cases were included in the sub-cohort. Participants not officially registered as inhabitants in 
Tromsø or Nord-Trøndelag at baseline (n=3) were excluded. Further, we excluded participants with 
missing values for at least one of the single nucleotide polymorphisms (SNPs) studied (n=175), and 
participants with missing data on FHMI (n=2,769) and BMI (n=52). Consequently, 1,164 incident VTEs 
and 10,402 sub-cohort participants were included in the study. The study was approved by the 
Regional Committees for Medical and Health Research Ethics, and all study participants provided 





Classification of VTE events 
VTE events were classified as provoked and unprovoked, depending on the presence of provoking 
factors at the time of diagnosis. In the Tromsø Study, provoking factors were active cancer, acute 
medical conditions (including acute MI, ischemic stroke or major infections), recent surgery or trauma 
within the previous eight weeks, immobilization (bed rest over three days, wheelchair use or long 
distance travel exceeding four hours the last 14 days prior to the event) or any other provoking factors 
described by a physician in the medical record (e.g. intravascular catheter). In the HUNT study, 
provoking factors included active cancer at the time of the event or within six months after the event, 
trauma, surgery or marked immobilization (paresis, paralysis, prolonged bed rest due to an acute 
medical illness or travel exceeding 8 hours) within the last three months, pregnancy or puerperium at 
the time of the event and oral contraceptives used at the time of the event or up to one month prior 
to the event.  
 
Cardiovascular risk factors 
Baseline information on cardiovascular risk factors was collected by physical examinations, blood 
samples, and self-administered questionnaires. Height and weight were measured with participants 
wearing light clothing and no shoes. Body mass index (BMI) was calculated as weight in kilograms 
divided by the square of height in meter (kg/m2). Blood pressure was measured three times with an 
automatic device (Dinamap Vital Signs Monitor in the Tromsø Study and Dinamap 845XT [Critikon] in 
the HUNT study) in a sitting position after two minutes of rest. The average of the two last readings 
was used in the analyses. Non-fasting blood samples were collected from an antecubital vein and total 
cholesterol, triglycerides and high-density lipoprotein (HDL) were measured, as previously described 
[7, 20]. Self-administered questionnaires were used to obtain information on diabetes, smoking 
(current daily smoking, yes/no) and FHMI. To identify FHMI, subjects were asked to report whether 




60 years. A positive family history was regarded as ≥ 1 first-degree relative with a history of MI before 
the age of 60 years. 
 
Prothrombotic genotypes 
The following single nucleotide polymorphisms (SNPs) were genotyped and used in the present study: 
rs8176719 in ABO (non-O blood type), rs6025 in F5 (Factor V Leiden), rs1799963 in F2 (prothrombin 
G20210A), rs2066865 in FGG and rs2036914 in F11. In the Tromsø Study, rs8176719 (ABO), rs6025 
(F5), rs1799963 (F2) and rs2036914 (F11) were genotyped with the Sequenom platform, and 
rs2066865 (FGG) with the TaqMan platform, as previously described [23]. The HUNT study performed 
genotyping using the Illumina HumanCore Exome array. 
Participants were considered carriers of the prothrombotic risk gene when one or two risk 
alleles were present. We did not differentiate between hetero- and homozygous carriers due to the 
low number of homozygous carriers. For rs2036914 in F11, the minor allele was associated with 
reduced risk of VTE, and in this case, we considered the common allele as the risk allele [24]. For 
rs8176719 (ABO), zero risk alleles were classified as O blood type, whereas one or two risk alleles were 
classified as non-O blood type. The 5-SNP score conceived by de Haan and colleagues was created by 
summarizing the number of risk alleles from the five sequenced SNPs [25]. As homozygous individuals 
have two risk alleles, the potential maximum number of risk alleles in the 5-SNP score would be 10. 
 
Statistical analysis 
Statistical analyses were carried out using STATA version 14.0 and 15.0 (Stata Corporation, College 
Station, TX, USA). For each participant, person-years of follow-up were counted from the date of 
enrollment (1994-1995 in the Tromsø Study and 1995-1997 in the HUNT Study) to the date of an 




or until the end of the study period (December 31, 2008 in the HUNT study and December 31, 2012 in 
the Tromsø Study). Participants who died or moved from Tromsø or Nord-Trøndelag County during 
follow-up were censored at the date of death or migration.  
Cox proportional hazards regression models were used to estimate hazard ratios (HRs) with 
95% confidence intervals (CIs) for VTE by FHMI and prothrombotic genotypes. Age was used as the 
time-scale, with the age of the participants at study enrolment defined as entry time, and the age at 
the VTE or censoring event defined as exit time. All analyses were adjusted for age (as time-scale), sex 
and BMI. We estimated the risk of total VTE, as well as unprovoked VTE and provoked VTE, by FHMI 
and according to ≥ 1 affected relatives or ≥ 1 affected parent, respectively. In order to assess the role 
of prothrombotic genotypes on the association between FHMI and VTE, the five SNPs were entered 
into the regression models. Furthermore, to investigate combined effects, we calculated HRs of VTE 
according to categories of FHMI and the individual SNPs as well as categories of the 5-SNP score (0-1, 
2, 3-4 and ≥ 5 risk alleles). The presence of biological interaction between the two exposures was 
assessed by calculating the relative excess risk due to interaction (RERI), the attributable proportion 
due to interaction (AP) and the synergy index (SI) with corresponding 95% CIs [26].  Briefly, the RERI 
can be interpreted as part of the total effect on the outcome that is due to interaction, and the AP as 
the proportion of cases in the combined group that is due to an interaction between the two 
exposures. RERI and AP > 0 and SI > 1.0 suggest positive interaction, i.e., the effect of the joint 
exposures to two risk factors is greater than the sum of the separate effects [26].  
Because of the size of the sub-cohort, we did not make adjustments to the partial likelihood in 
the Cox regression analyses [27]. The proportional hazard assumption was tested using Schoenfeld 
residuals. Lastly, we performed a sensitivity analysis in which participants with missing information on 
FHMI were included in the study and categorized as not having FHMI (i.e. assuming that all missings 






The baseline characteristics of the cases and the sub-cohort are shown in Table 1. Participants who 
experienced a VTE were older and had slightly higher systolic blood pressure, BMI, triglycerides, and 
cholesterol levels compared with participants in the sub-cohort. Serum levels of triglycerides and total 
cholesterol along with the proportion of smokers and participants with self-reported diabetes were 
higher in the group with a FHMI. Compared to the sub-cohort, VTE patients had a higher proportion of 
participants with ≥ 1 risk allele(s) in all SNPs, and rs8176719 (ABO), rs6025 (F5), and rs1799963 (F2) in 
particular.  The prevalence of the SNPs did not differ according to FHMI.  
The distribution of individuals (%) across numbers of risk alleles for subjects with and without 
FHMI is shown in Figure 2, panel A. The number of risk alleles ranged from zero to seven with a median 
of two for both groups, and participants with and without FHMI had a similar distribution of the 
number of risk alleles. The risk of VTE (Figure 2, panel B) increased with increasing number of risk 
alleles when compared to zero risk alleles (p for trend<0.001). Subjects with ≥ 5 risk alleles had a 2.4-
fold higher risk of VTE (HR 2.43, 95% CI 1.64-3.59) compared with those without risk alleles.  
Table 2 shows HRs for total, unprovoked and provoked VTE by FHMI. In models adjusted for 
age (as time-scale), sex and BMI, subjects with ≥ 1 affected first-degree relative or ≥ 1 affected parent 
had increased risk of VTE with a HR of 1.32 (95% CI 1.16-1.50) and 1.40 (95% CI 1.20-1.64), respectively. 
The point estimate for unprovoked VTE (HR 1.47, 95% CI 1.22-1.78) was higher than for provoked VTE 
(HR 1.20, 95% CI 1.00-1.43). Similarly to total VTE, the risk estimates for unprovoked VTE were higher 
in the analysis of ≥ 1 affected parent (HR 1.52, 95% CI 1.20-1.93) in comparison with ≥ 1 affected first-
degree relative (HR 1.47, 95% CI 1.22-1.78). Adjustments for the five prothrombotic genotypes had a 
negligible effect on the risk estimates for VTE. Sensitivity analyses where participants with missing 





Table 3 shows HRs with 95% CI for total VTE and unprovoked VTE by combinations of FHMI 
and prothrombotic genotypes, adjusted for age (as time-scale), sex and BMI. For each of the individual 
SNPs, the risk of VTE was increased in participants having a positive FHMI and no risk alleles, and in 
participants without FHMI and ≥ 1 risk alleles. However, the combined effect of having both FHMI and 
≥ 1 risk alleles did not exceed the sum of the effects of the individual risk factors. For instance, having 
both FHMI and non-O blood type (rs8176719) was associated with a 1.8-fold increased risk of VTE (HR 
1.78, 95% CI 1.49-2.13), which approximated the sum of having only FHMI (HR 1.35, 95% CI 1.07-1.71) 
or non-O blood type (HR 1.38, 95% CI 1.19-1.59). The combination of FHMI and the high-risk category 
of the 5-SNP score (i.e. ≥ 5 risk alleles) did not have a synergistic impact on the VTE risk (RERI 0.37, 95% 
CI -0.89 to 1.63 and AP 0.14, 95% CI -0.29 to 0.56). Thus, combinations of FHMI and prothrombotic 
genotypes had merely additive effects on the VTE risk, as suggested by the estimated measures of 
biological interaction (i.e. RERI, AP, and SI) described in Supplementary Tables 2 and 3.      
 
Discussion 
In this case-cohort study with participants recruited from the general population, we found that the 
association between FHMI and VTE could not be explained by common prothrombotic genotypes, such 
as rs8176719 (ABO), rs6025 (F5), rs1799963 (F2), rs2066865 (FGG), and rs2036914 (F11). Adjustment 
for prothrombotic genotypes did not alter the association between FHMI and VTE, and the 
combination of FHMI and prothrombotic genotypes had merely an additive effect on the VTE risk.  
The increased risk of VTE, and particularly unprovoked VTE, by a FHMI is in agreement with 
results from other observational studies [9-11, 14]. In two previous studies with data from the entire 
Tromsø cohort, FHMI was associated with a 1.3-fold increased risk of VTE [9, 11], and a 1.5-fold 
increased risk of unprovoked VTE [9, 11]. Adjustment for traditional cardiovascular risk factors had a 
negligible effect on the risk of VTE [9, 11], whereas the risk of MI was attenuated [11], indicating that 




association between FHMI and VTE [11]. Similar results were reported in a case-cohort derived from 
the second survey of the HUNT study [10], and a case-control study derived from the Genetic Attributes 
and Thrombosis Epidemiology (GATE) study [14]. Sub-group analyses from the different studies 
revealed that the risk of VTE increased with increasing number of affected relatives [11, 14], and when 
a relative aged < 50 years experienced an MI [14]. Further, the reported risk estimates for DVT and PE 
were similar, but the risk was highest for unprovoked DVTs [11]. A FHMI is not considered to be a 
causal factor for thrombosis, but rather an indicator of genetic or environmental risk factors 
accumulating in certain families, which have the potential to affect the risk of VTE. Due to the 
particularly increased risk of unprovoked VTE, and because the risk increases with increasing numbers 
of affected relatives, it was suggested that the association between FHMI and VTE was caused by 
shared genetic risk factors [9-11, 14]. 
In the present study, rs8176719 (ABO), rs6025 (F5), rs1799963 (F2), rs2066865 (FGG), and 
rs2036914 (F11) did not act as confounders in the association between FHMI and VTE, as adjustments 
for these prothrombotic genotypes had a negligible effect on the risk estimates. Furthermore, 
combinations of FHMI and the prothrombotic genotypes had an additive effect on the risk of VTE. For 
instance, having both FHMI and rs8176719 (ABO) was associated with a 1.8-fold increased risk of VTE, 
which was equal to the sum of having only FHMI or rs8176719 (ABO). Similar results were found for 
FHMI in combination with the other individual SNPs and the combined 5-SNP score. Our results suggest 
that FHMI and the five prothrombotic genotypes included in this study are unrelated risk factors of 
VTE and that these prothrombotic genotypes do not influence the association between FHMI and VTE.  
Two risk factors acting through the same pathophysiological mechanism can have both 
synergistic and additive effects on an outcome. For instance, obesity and rs6025 (F5), which are 
associated with hypercoagulability, had synergistic effects on VTE risk [28]. Similarly, the risk of VTE in 
obese women using oral contraceptives has been shown to exceed the sum of the effects of the 
individual risk factors [29]. However, a cohort study of 66,000 genotyped participants found additive 




combined [30]. Consequently, our results do not allow us to determine the mechanisms behind the 
association between FHMI and VTE, and do not exclude the possibility that other unrecognized genetic 
variants can partly explain the association between FHMI and VTE. 
Even though the prothrombotic genotypes included in our study are associated with both 
arterial and venous thrombosis [15-18], our results indicate that these genotypes do not explain the 
association between FHMI and VTE. However, on the basis of the present and previous findings [9, 11], 
it is likely to assume that genetic risk factors are one of the main contributors to the association 
between FHMI and VTE. Furthermore, environmental risk factors clustering within families may 
potentially act as contributors to this association. Although the association between FHMI and VTE is 
independent of traditional cardiovascular risk factors [9-11], other environmental risk factors related 
to both FHMI and VTE, such as stress and socioeconomic status [31-33], might partly explain the 
association.   
The main strengths of our study include the long-term follow-up, the large number of 
genotyped participants, the high attendance rate in the parent cohorts, and the thorough outcome 
assessment. The study cohorts represent a general and homogenous Caucasian population, which 
limits confounding by ethnicity in the sub-cohort [34]. Some limitations of this study need to be 
addressed. First, analyses were restricted to subjects with information on FHMI. It is likely to assume 
that the majority of subjects with missing information on FHMI did not answer the question because 
they did not have, or did not know if they had, any first-degree relatives with a history of MI before 
the age of 60 years. It is noteworthy, however, that the association between FHMI and VTE, albeit 
slightly attenuated, remained when participants with missing data on FHMI were classified as having 
no FHMI (Supplementary table 1). Second, data on FHMI was self-reported and both under-reporting 
and over-reporting of affected relatives were possible. Validation of FHMI in the Tromsø Study showed 
high concurrence between reported and confirmed diagnosis [35], and a validation study by Kee et al. 
found high specificity (97%) and lower sensitivity (68%) of a positive FHMI [36]. Hence, 




derived from large cohorts, the number of VTE events was low in some subgroups, particularly for the 
rare exposures, which resulted in limited statistical power. Our results on the measures that quantify 
interaction should therefore be interpreted with caution. Lastly, due to the observational nature of 
our study, unknown confounders could be present and lead to residual confounding.  
In conclusion, our study provides evidence that the association between FHMI and VTE is not 
explained by rs8176719 (ABO), rs6025 (F5), rs1799963 (F2), rs2066865 (FGG) or rs2036914 (F11). FHMI 
and the prothrombotic genotypes had an additive effect on VTE risk, indicating no biological 
interaction between the risk factors. 
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Table 1. Baseline characteristics by family history of myocardial infarction (FHMI) and incident 
venous thromboembolism (VTE).  
 No FHMI  FHMI 
 Sub-cohort VTE  Sub-cohort VTE 
Participants, n 8376 851  2026 313 
Age, years 49.8±17 60.7±15  52.7±15 59.9±14 
Male sex 46.0 (3857) 49.6 (422)  42.9 (869) 42.5 (133) 
Systolic BP, mmHg 137±21 144±24  140±21 144±23 
Diastolic BP, mmHg 80±12 83±13  82±12 82±12 
BMI, kg/m2 26.1±4.1 27.5±4.6  26.5±4.2 27.4±4.2 
Triglycerides, mmol/L 1.68±1.04 1.80±0.99  1.82±1.09 1.95±1.32 
Cholesterol, mmol/L 5.88±1.26 6.34±1.28  6.26±1.32 6.63±1.28 
HDL, mmol/L 1.41±0.39 1.43±0.41  1.41±0.40 1.42±0.41 
Self-reported diabetes 2.9 (244) 3.8 (32)  3.9 (80) 4.5 (14) 
Smoking 27.1 (2269) 25.7 (219)  31.9 (646) 31.6 (99) 
rs8176719 (ABO)* 61.4 (5139) 69.1 (588)  63.4 (1284) 69.0 (216) 
rs6025 (F5)* 6.8 (571) 15.3 (130)  7.2 (146) 16.0 (50) 
rs1799963 (F2)* 1.2 (104) 1.8 (15)  1.5 (31) 3.2 (10) 
rs2066865 (FGG)* 41.9 (3508) 44.1 (375)  44.6 (903) 50.2 (157) 
rs2036914 (F11)* 78.5 (6572) 80.4 (684)  76.7 (1553) 82.1 (257) 
Values are % (n) or mean±SD. BP indicating blood pressure; BMI, body mass index; HDL, high-density 
lipoprotein. 











Table 2. Hazard ratios (HR) with 95% confidence intervals (CI) for total, unprovoked and provoked 
venous thromboembolism (VTE) by family history of myocardial infarction (FHMI).  
 N Events HR (95% CI)* Adjusted HR (95% CI)† 
Total VTE  1164   
No FHMI  9227 851 Ref. Ref. 
≥ 1 first-degree relative 2339 313 1.32 (1.16-1.50) 1.30 (1.14-1.48) 
≥ 1 affected parent 1673 197 1.40 (1.20-1.64) 1.41 (1.20-1.65) 
Unprovoked VTE  513   
No FHMI 9227 363 Ref. Ref. 
≥ 1 first-degree relative 2339 150 1.47 (1.22-1.78) 1.45 (1.20-1.76) 
≥ 1 affected parent 1673 90 1.52 (1.20-1.92) 1.53 (1.21-1.93) 
Provoked VTE  651   
No FHMI 9227 488 Ref. Ref. 
≥ 1 first-degree relative 2339 163 1.20 (1.00-1.43) 1.19 (0.99-1.42) 
≥ 1 affected parent 1673 107 1.32 (1.07-1.63) 1.32 (1.07-1.63) 
*Adjusted for age (as time-scale), sex and body mass index 
†Adjusted for age (as time-scale), sex, body mass index, rs8176719 (ABO), rs6025 (F5), rs1799963 








Table 3. Hazard ratios (HR) with 95% confidence intervals (CI) for venous thromboembolism (VTE) by 
combined categories of family history of myocardial infarction (FHMI) and prothrombotic genotypes.  
   Total VTE  Unprovoked VTE 
 N  Events HR (95% CI)*  Events HR (95% CI)* 
FHMI rs8176719 (ABO)†        
- - 3500  263 Ref.  107 Ref. 
+ - 839  97 1.35 (1.07-1.71)  49 1.67 (1.19-2.34) 
- + 5727  588 1.38 (1.19-1.59)  256 1.47 (1.17-1.84) 
+ + 1500  216 1.78 (1.49-2.13)  101 2.04 (1.55-2.68) 
FHMI rs6025 (F5)†        
- - 8526  721 Ref.  296 Ref. 
+ - 2143  263 1.31 (1.14-1.51)  129 1.56 (1.27-1.92) 
- + 701  130 2.31 (1.92-2.79)  67 2.92 (2.24-3.81) 
+ + 196  50 3.09 (2.32-4.12)  21 3.16 (2.03-4.93) 
FHMI rs1799963 (F2)†        
- - 9108  836 Ref.  355 Ref. 
+ - 2298  303 1.30 (1.14-1.49)  145 1.46 (1.20-1.77) 
- + 119  15 1.41 (0.85-2.35)  8 1.77 (0.88-3.57) 
+ + 41  10 2.49 (1.33-4.64)  5 2.91 (1.20-7.04) 
FHMI rs2066865 (FGG)†        
- - 5344  476 Ref.  198 Ref. 
+ - 1279  156 1.22 (1.02-1.47)  76 1.42 (1.09-1.86) 
- + 3883  375 1.10 (0.96-1.26)  165 1.17 (0.95-1.43) 
+ + 1060  157 1.56 (1.30-1.87)  74 1.77 (1.35-2.31) 
FHMI rs2036914 (F11)†        
- - 1971  167 Ref.  60 Ref. 
+ - 529  56 1.16 (0.86-1.57)  20 1.15 (0.69-1.91) 
- + 7256  684 1.11 (0.94-1.31)  303 1.37 (1.04-1.80) 
+ + 1810  257 1.50 (1.24-1.83)  130 2.11 (1.55-2.87) 
FHMI 5-SNP score‡        
- 0-1 2117  154 Ref.  53 Ref. 
+ 0-1 484  46 1.16 (0.83-1.61)  21 1.52 (0.92-2.52) 
- 2 2888  217 1.03 (0.84-1.26)  98 1.35 (0.96-1.88) 
+ 2 716  83 1.38 (1.06-1.80)  37 1.77 (1.16-2.69) 
- 3-4 3833  420 1.49 (1.24-1.80)  186 1.92 (1.41-2.60) 
+ 3-4 1026  160 2.02 (1.62-2.52)  80 2.94 (2.07-4.16) 
- ≥5 389  60 2.16 (1.60-2.91)  26 2.73 (1.71-4.36) 
+ ≥5 113  24 2.69 (1.75-4.13)  12 3.88 (2.07-7.28) 
*Adjusted for age (as time-scale), sex and body mass index 
†Positive indicating subjects with one or two risk alleles 





Figure 1. Study population. Participants were recruited from the fourth survey of the Tromsø Study 
(1994-2012), and from the second survey of the Nord-Trøndelag Health (HUNT) Study (1995-2008). 
VTE indicates venous thromboembolism; SNPs, single nucleotide polymorphisms; FHMI, family 
history of myocardial infarction. 
 
Figure 2. Panel A. Distribution (%) of individuals across number of risk alleles and family history of 
myocardial infarction (FHMI). 
 
Figure 2. Panel B. Hazard ratios with 95% confidence intervals for the risk of venous 
thromboembolism (VTE) by number of risk alleles in the 5-SNP score. 
